Mon, June 4, 2012
Sat, June 2, 2012
Fri, June 1, 2012
Thu, May 31, 2012
Wed, May 30, 2012
Tue, May 29, 2012
Mon, May 28, 2012
Sun, May 27, 2012
Sat, May 26, 2012
Fri, May 25, 2012
[ Fri, May 25th 2012 ] - Market Wire
GenVec Reports Inducement Award
Thu, May 24, 2012
Wed, May 23, 2012
[ Wed, May 23rd 2012 ] - Market Wire
Moody's Upgrades Mylan
Tue, May 22, 2012
Mon, May 21, 2012

Omeros to Present at Jefferies 2012 Global Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. jefferies-2012-global-healthcare-conference.html
Published in Health and Fitness on Tuesday, May 29th 2012 at 4:05 GMT by Market Wire   Print publication without navigation


Omeros to Present at Jefferies 2012 Global Healthcare Conference -- SEATTLE, May 29, 2012 /PRNewswire/ --

Omeros to Present at Jefferies 2012 Global Healthcare Conference

[ ]

SEATTLE, May 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference next week.  The presentation is scheduled for 4:30 p.m. Eastern Time on Monday, June 4, 2012.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

[ Back to top ]

RELATED LINKS
[ http://www.omeros.com ]


Publication Contributing Sources